Back to Newsroom

CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine

TUEBINGEN, Germany, Oct. 3, 2013 – CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac’s RNActive(R) technology.